NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis $4.79 +0.22 (+4.81%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.53▼$4.8350-Day Range$3.60▼$4.9152-Week Range$1.53▼$8.95Volume336,211 shsAverage Volume1.00 million shsMarket Capitalization$246.21 millionP/E RatioN/ADividend YieldN/APrice Target$12.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get 2seventy bio alerts: Email Address 2seventy bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside159.5% Upside$12.43 Price TargetShort InterestBearish15.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 3 Articles This WeekInsider TradingSelling Shares$7,665 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.93) to $0.76 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector610th out of 936 stocksPharmaceutical Preparations Industry281st out of 436 stocks 3.3 Analyst's Opinion Consensus Rating2seventy bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst Coverage2seventy bio has only been the subject of 4 research reports in the past 90 days.Read more about 2seventy bio's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.15% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in 2seventy bio has recently increased by 24.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSVT. Previous Next 3.3 News and Social Media Coverage News Sentiment2seventy bio has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for 2seventy bio this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,665.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 2seventy bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($0.93) to $0.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 2seventy bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About 2seventy bio Stock (NASDAQ:TSVT)2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More TSVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSVT Stock News HeadlinesJuly 5, 2024 | investorplace.com3 Hidden Stock Gems That Wall Street Is OverlookingJune 26, 2024 | businesswire.com2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 millionJuly 26, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…May 23, 2024 | businesswire.com2seventy bio to Participate in Upcoming Investor ConferencesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 2seventy bio on Strong Growth Prospects and Financial StabilityMay 9, 2024 | msn.com2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.com2seventy bio Inc (TSVT) Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic RealignmentsMay 9, 2024 | uk.finance.yahoo.com2seventy bio Inc (TSVT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and ...July 26, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…May 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from 2seventy bio's earningsMay 8, 2024 | investorplace.comTSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024May 8, 2024 | businesswire.com2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressMay 3, 2024 | finance.yahoo.com2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024May 3, 2024 | businesswire.com2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024April 17, 2024 | msn.com2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's WhyApril 13, 2024 | morningstar.com2seventy bio Inc Ordinary SharesApril 10, 2024 | investing.comCiti raises 2Seventy Bio stock target on FDA approvalApril 8, 2024 | markets.businessinsider.comPositive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive DynamicsSee More Headlines Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TSVT CUSIPN/A CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees274Year FoundedN/APrice Target and Rating Average Stock Price Target$12.43 High Stock Price Target$26.00 Low Stock Price Target$2.00 Potential Upside/Downside+161.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($4.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,570,000.00 Net Margins-313.51% Pretax Margin-313.51% Return on Equity-67.59% Return on Assets-31.71% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick Ratio3.52 Sales & Book Value Annual Sales$100.39 million Price / Sales2.44 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.94Miscellaneous Outstanding Shares51,400,000Free Float47,704,000Market Cap$244.66 million OptionableOptionable Beta1.76 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Nick Leschly (Age 51)President & Chairman of the Board Comp: $1.81MMr. William D. Baird III (Age 52)M.B.A., CEO & Director Comp: $810.83kVicki EatwellChief Financial OfficerJessica SnowSenior VP of Quality and Head of OperationsMichael CertoVP & Head of Genome EditingAnna Truppel-HartmannChief Medical OfficerMore ExecutivesKey CompetitorsPacira BioSciencesNASDAQ:PCRXAbCellera BiologicsNASDAQ:ABCLImmunomeNASDAQ:IMNMLiquidiaNASDAQ:LQDACogent BiosciencesNASDAQ:COGTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 10,077 shares on 7/26/2024Ownership: 0.383%Nisa Investment Advisors LLCBought 13,561 shares on 7/20/2024Ownership: 0.026%Victoria EatwellSold 1,167 sharesTotal: $4,878.06 ($4.18/share)Jessica SnowSold 649 sharesTotal: $2,712.82 ($4.18/share)Jacobs Levy Equity Management Inc.Bought 379,586 shares on 5/16/2024Ownership: 0.738%View All Insider TransactionsView All Institutional Transactions TSVT Stock Analysis - Frequently Asked Questions How have TSVT shares performed this year? 2seventy bio's stock was trading at $4.27 on January 1st, 2024. Since then, TSVT shares have increased by 12.2% and is now trading at $4.79. View the best growth stocks for 2024 here. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) released its earnings results on Wednesday, May, 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.09. The firm had revenue of $12.44 million for the quarter, compared to the consensus estimate of $11.93 million. 2seventy bio had a negative trailing twelve-month return on equity of 67.59% and a negative net margin of 313.51%. Who are 2seventy bio's major shareholders? 2seventy bio's top institutional investors include Bank of New York Mellon Corp (0.38%) and Nisa Investment Advisors LLC (0.03%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, Nick Leschly, Philip D Gregory, William D Baird III, Victoria Eatwell, Nicola Heffron and Jessica Snow. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSVT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSVT Stock Alerts